The Flt3 internal tandem duplication mutant inhibits the function of transcriptional repressors by blocking interactions with SMRT

DOI PDF 被引用文献4件
  • Shinichiro Takahashi
    From the Division of Hematology/Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, NY; Departments of Molecular Diagnostics, Rheumatology and Hematology, Tohoku University School of Medicine, Sendai, Japan; and Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY.
  • Melanie J. McConnell
    From the Division of Hematology/Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, NY; Departments of Molecular Diagnostics, Rheumatology and Hematology, Tohoku University School of Medicine, Sendai, Japan; and Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY.
  • Hideo Harigae
    From the Division of Hematology/Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, NY; Departments of Molecular Diagnostics, Rheumatology and Hematology, Tohoku University School of Medicine, Sendai, Japan; and Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY.
  • Mitsuo Kaku
    From the Division of Hematology/Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, NY; Departments of Molecular Diagnostics, Rheumatology and Hematology, Tohoku University School of Medicine, Sendai, Japan; and Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY.
  • Takeshi Sasaki
    From the Division of Hematology/Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, NY; Departments of Molecular Diagnostics, Rheumatology and Hematology, Tohoku University School of Medicine, Sendai, Japan; and Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY.
  • Ari M. Melnick
    From the Division of Hematology/Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, NY; Departments of Molecular Diagnostics, Rheumatology and Hematology, Tohoku University School of Medicine, Sendai, Japan; and Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY.
  • Jonathan D. Licht
    From the Division of Hematology/Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, NY; Departments of Molecular Diagnostics, Rheumatology and Hematology, Tohoku University School of Medicine, Sendai, Japan; and Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY.

抄録

<jats:title>Abstract</jats:title><jats:p>Fms-like tyrosine kinase 3 (Flt3) is a type III receptor tyrosine kinase (RTK). Between 20% and 30% of acute myeloid leukemia (AML) patients have either an internal tandem duplication (ITD) of the juxtamembrane region or a point mutation of the Flt3 receptor leading to the constitutive activation of downstream signaling pathways and aberrant cell growth. The silencing mediator of retinoic and thyroid hormone receptors (SMRT) corepressor mediates transcriptional repression by interacting with transcription factors such as the promyelocytic leukemia zinc finger (PLZF) protein. Previous reports indicate that SMRT interaction with transcription factors can be disrupted by phosphorylation through activation of RTK pathways. We report here that the Flt3-ITD interferes with the transcriptional and biologic action of the PLZF transcriptional repressor. In the presence of Flt3-ITD, PLZF-SMRT interaction was reduced, transcriptional repression by PLZF was inhibited, and PLZF-mediated growth suppression of leukemia cells was partially blocked. Furthermore, overexpression of Flt3-ITD led to a partial relocalization of SMRT protein from the nucleus to the cytoplasm. Nuclear export was dependent on the SMRT receptor interaction domain (RID), and Flt3-ITD enhances the binding of nuclear-cytoplasm shuttling protein nuclear factor-κB-p65 (NFκB-p65) to this region. These data suggest that activating mutations of Flt3 may disrupt transcriptional repressor function resulting in aberrant gene regulation and abnormal leukemia cell growth. (Blood. 2004;103:4650-4658)</jats:p>

収録刊行物

  • Blood

    Blood 103 (12), 4650-4658, 2004-06-15

    American Society of Hematology

被引用文献 (4)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ